Speakers
Melissa McNaughton
Karen Smith
Mark Strachan
Scotland
Session Chair: Melissa McNaughton
2.15pm Karen Smith, Past, present and future of specialist endocrine testing
2.35pm Mark Strachan, C-peptide measurement in diabetes
3.00pm Kirsty Duncan, Islet cell transplant
3.20pm Ian Hunter, Diabetes in adolescence
ACB Scotland would like to invite you to our session at UKMedLab which will explore current and future advances in the diagnosis and treatment of diabetes as well as taking a broader look at where we have come from in the landscape of specialist endocrine testing. We have chosen this topic to showcase the talent we have in Scotland in this ever relevant area of clinical biochemistry and also to highlight particular success stories. We hope you find the session interesting and stimulating, we as organisers are certainly happy with how our session has come together. See you there!
The ACB Scotland Committee
Past, present and future of specialist endocrine testing - Karen Smith
I will talk about the developments in methodology for measuring hormones across the 30 years of my career in clinical biochemistry
C-peptide measurement in diabetes - Mark Strachan
C-peptide is a measure of endogenous insulin secretion and has a well-established role in determining the aetiology of spontaneous hypoglycaemia. In recent years, there has been considerable interest in the utility of serum or urine C-peptide in helping to determine more accurately the correct aetiology of diabetes. In this presentation, I shall demonstrate the impact that serum C-peptide testing had on diabetes diagnosis in one UK centre. In addition, I shall consider the prognostic significance of retained, detectable C-peptide in people with Type 1 diabetes, with regards to vascular and metabolic complications. Finally, I shall consider whether C-peptide has a role in people with Type 2 diabetes with respect to choosing the most appropriate anti-diabetic therapy.
Islet cell transplant - Kirsty Duncan
Islet cell transplant is a treatment for people with type 1 diabetes mellitus who have severe impaired awareness of hypoglycaemia despite intensive insulin management. This can often be life threatening. Islet cell transplant is a way of restoring hypoglycaemic awareness in this group of patients with prevention of further significant hypoglycaemia. This can include insulin independence in some patients.
Diabetes in adolescence - Ian Hunter
Melissa McNaughton is a principal clinical biochemist working at Glasgow Royal Infirmary. Melissa trained in NHS Lothian, Edinburgh before moving to NHS Greater Glasgow and Clyde. Melissa is the current meeting secretary for ACB Scotland. Before this she served as the ACB trainee representative for East of Scotland.
Mark Strachan is a consultant in Endocrinology, Diabetes and Acute Medicine at the Western General Hospital, Edinburgh and Honorary Professor of the University of Edinburgh. He has a long interest of diagnostic accuracy in diabetes and runs a clinic for people with monogenic forms of diabetes. He is a former RD Lawrence lecturer of Diabetes UK.
He was Trustee and Treasurer of the British Thyroid Foundation for 13 years and is a member of the National Cancer Research Institute committee on thyroid cancer. He is Secretary of the Royal College of Physicians of Edinburgh and former President of the Scottish Society of Physicians. He is an editor of the international textbook ‘Davidson’s Principles and Practice of Medicine’.
I am an Islet Cell Recipient Transplant Coordinator at Edinburgh Royal Infirmary working within the Beta Cell Replacement Service. This is a national programme covering Scotland and Northern Ireland providing transplant options for people mainly with Type 1 Diabetes Mellitus. I have worked in islet cell transplantation since the programme received national funding from NSD in 2009.
